Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.

RPEP-095132024Wedemeyer, Heiner; Aleman, Soo; Brunetto, Maurizia; Blank, Antje; Andreone, Pietro; Bogomolov, Pavel; Chulanov, Vladimir; Mamonova, Nina; Geyvandova, Natalia; Morozov, Viacheslav; Sagalova, Olga; Stepanova, Tatyana; Berger, Annemarie; Ciesek, Sandra; Manuilov, Dmitry; Mercier, Renee-Claude; Da, Ben L; Chee, Grace M; Li, Mingyang; Flaherty, John F; Lau, Audrey H; Osinusi, Anu; Schulze Zur Wiesch, Julian; Cornberg, Markus; Zeuzem, Stefan; Lampertico, Pietro

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.

Journal of hepatology, 81(4), 621-629

View on PubMed ↗Publisher’s paper ↗

Citation

Wedemeyer, Heiner; Aleman, Soo; Brunetto, Maurizia; Blank, Antje; Andreone, Pietro; Bogomolov, Pavel; Chulanov, Vladimir; Mamonova, Nina; Geyvandova, Natalia; Morozov, Viacheslav; Sagalova, Olga; Stepanova, Tatyana; Berger, Annemarie; Ciesek, Sandra; Manuilov, Dmitry; Mercier, Renee-Claude; Da, Ben L; Chee, Grace M; Li, Mingyang; Flaherty, John F; Lau, Audrey H; Osinusi, Anu; Schulze Zur Wiesch, Julian; Cornberg, Markus; Zeuzem, Stefan; Lampertico, Pietro. (2024). Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.. Journal of hepatology, 81(4), 621-629. https://doi.org/10.1016/j.jhep.2024.05.001